Keytruda® (pembrolizumab) – Expanded indication

Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. May 5, 2021

Pfizer COVID-19 Vaccine – Expanded use in adolescents 12 – 15 years old

The FDA approved an expansion to the Emergency Use Authorization (EUA) for the coronavirus disease 2019 (COVID-19) vaccine produced by Pfizer/BioNTech to include adolescents age 12 – 15 years. May 10, 2021